{"id":"NCT02254265","sponsor":"Sun Pharmaceutical Industries Limited","briefTitle":"Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","officialTitle":"A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-09","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2014-10-01","resultsPosted":"2018-12-14","lastUpdate":"2022-08-29"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Keratoconjunctivitis Sicca","Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"OTX-101 0.05%","otherNames":[]},{"type":"DRUG","name":"OTX-101 0.09%","otherNames":[]},{"type":"DRUG","name":"Vehicle","otherNames":[]}],"arms":[{"label":"OTX-101 0.05%","type":"EXPERIMENTAL"},{"label":"OTX-101 0.09%","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 2/3 study to evaluate the safety and efficacy of 2 different dose concentrations of OTX-101 dosed twice a day in both eyes for 84 days compared to placebo (vehicle) in patients with keratoconjunctivitis sicca (dry eye disease).","primaryOutcome":{"measure":"Conjunctival Staining","timeFrame":"Baseline to 84 days","effectByArm":[{"arm":"OTX-101 0.05%","deltaMin":-1.9,"sd":2.17},{"arm":"OTX-101 0.09%","deltaMin":-1.8,"sd":2.27},{"arm":"Vehicle","deltaMin":-1.2,"sd":2.17}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":152},"commonTop":["Instillation site pain","Eye pruritus","Nasopharyngitis","Eye irritation","Lacrimation increased"]}}